HELP US GROW THE COLLECTION! Submit a compound here.
The Drug Repurposing Hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds with a companion information resource. Order library plates to screen yourself or collaborate with the Broad Institute’s Center for the Development of Therapeutics to see if an existing drug may work against your novel target, model system, or indication. While the collection will undoubtedly reveal new uses for developed drugs, its true power is unlocked when applied to discover new biological insights and disease mechanisms.
June 3, 2020
New molecular glue mechanism discovered Nature
February 20, 2020
Screening results featured in Cell
January 20, 2020
Screening results featured in Nature Cancer
This collection of drugs has been made possible in part by the generous support of philanthropic donors. Access to the library is currently subsidized thanks to donations. If you would like to help us continue to expand this library and increase the chances of matching existing drugs with unmet therapeutic needs, please learn about ways to give here.
Another way to participate in the effort is to suggest and/or share compounds to add to the collection. Download the policy for compound intake, and then submit a compound. For more information, contact us
Sars-CoV-2 continues to wreak havoc worldwide despite vaccination efforts. Small molecules offer a widely accepted and much needed treatment option. In searching for new protein-degrading molecular glues, Patten, et al screened the 6710-compound library for compounds that block the virus’s ability to reproduce itself in host cells. They found 172 strongly active hits that variously affect nearly every step of viral replication, offering a valuable toolkit for understanding such feats of replication. The most promising, obatoclax, has reached a Phase III clinical trial for the treatment of multiple cancers with known safety profile.
Reference datasets generated using the Drug Repurposing Hub compound library are a rich resource that can catalyze additional discoveries. In searching for new protein-degrading molecular glues, Slabicki, et al asked: is there a compound whose anti-cancer activity correlates with increasing expression of a protein involved in protein degradation? The answer was yes and, using data from the PRISM repurposing project and the Cancer Cell Line Encyclopedia, investigators identified a compound called CR8. Based on experimental and crystallographic studies, CR8 can now be added to the ranks of the highly sought-after protein-degrading molecular glues.
Mucin-1 Kidney Disease is caused by intracellular accumulation of a toxic Muc1 protein that cannot be delivered to its requisite location. This leads to kidney failure and at present no therapy is available. Dvela-Levitt et al. screened the drug repurposing library and found a compound that releases the toxic Muc-1 from its intracellular purgatory. Originally developed as an anti-hypertensive, BRD4780 is now a promising lead for the treatment of Mucin-1 Kidney Disease.
Watch: MUC1 Kidney Disease: Finding the roots of a molecular traffic jam
Despite staggering advances in immunotherapy, numerous cancers still remain untreatable. Corsello et al. screened 4,518 compounds against 578 cancer cell lines to identify new therapeutic candidates. Several non-oncology compounds revealed themselves to be potent cancer cell killers, including approved drugs such as the alcohol-dependence drug disulfiram and the anti-inflammatory drug tepoxalin. Many uncovered previously unknown mechanisms, thereby unlocking new targets for further exploration and drug development.
There is an urgent need for new approaches to combat antibiotic-resistant bacteria. Kulesa et al. screened the entire library to find molecules that would synergize with existing antibiotics. They identified 6 compounds, one of which had reached Phase I clinical trials. Despite the fact that 5 of these 6 compounds had never exhibited any antibiotic activity before, these compounds were shown to inhibit the growth of bacteria when used in combination with established antibiotics.
Toxoplasma gondii is a parasite transmitted by cats, whose acute infection in humans can be combated by antibiotics and by the body’s own immune defenses. To address the more difficult problem of chronic infection, Radke et al. screened the collection and discovered compounds that synergize with interferon gamma, a cytokine unleashed by immune system, to inhibit parasite growth.
Other projects using the resource for bioinformatics/computational analyses:
The Drug Repurposing Hub is a curated and annotated collection of FDA-approved drugs, clinical trial drugs, and pre-clinical tool compounds with a companion information resource. Order library plates to screen yourself or collaborate with the Broad Institute’s Center for the Development of Therapeutics to see if an existing drug may work against your novel target, model system, or indication. While the collection will undoubtedly reveal new uses for developed drugs, its true power is unlocked when applied to discover new biological insights and disease mechanisms.
We collaborate with many groups for screening, both at Broad and other institutions. The library is available as single-use, assay-ready plates at single or 4 concentrations that can be used at remote locations. Please see our screening information and contact repurposing@broadinstitute.org to discuss your project. We do not sell individual compounds.
No, the annotations provided in the Hub are freely available for research use by any organization. The information in the Repurposing Hub may not be repackaged or redistributed for commercial purposes without permission.
No. The drug library is being profiled by other projects such as the Connectivity Map, Cancer Dependency Map, and NIH LINCS. Please review project websites for information on data release.
Yes. The Repurposing Hub annotations are available via a RESTful web service as part of the Connectivity Map CLUE compute platform. See here for the CLUE API.
The Repurposing Hub compound metadata (including compound names, structures, targets, mechanisms, and indications) are made available under the permissive CC-BY 4.0 license. The data were generated and collected for research purposes only, and may not be used for clinical treatment or commercial marketing purposes. Please note that data/results from downstream experiments testing the Repurposing Hub compound library may be offered under different license terms.
With an executed Material Transfer Agreement in place, the library is currently available to academic and research institutes worldwide. The library is available as single-use, assay-ready plates; however, we do not sell individual compounds. Following a screen, compounds may be available to cherry-pick for concentration-response analysis. A per compound charge would apply.
The library is made available to non-profit institutions on a cost-recovery basis.
Note that to download repurposing annotation in batch format, the Drug information and Sample information downloadable files have relevant information and you do not need the API.
Steven Corsello
Founder of REPO Hub
Todd Golub
Core Institute Member
Sandy Gould
Director of Medicinal Chemistry, CDoT
Jaime Cheah
Associate Director of Scientific Outreach, CDoT
Chris Meyer
Chemistry Co-Lead
Ann Emmith
Associate Director of Data Informatics, CDoT
Anita Vrcic
Senior Lead of Compound Management, CDoT
Katherine Huang
Creative Director
Steve Johnston
Director of Discovery Solutions, CDoT
Jane McIninch
Project Manager, CDoT
We are deeply grateful for the generosity of an anonymous donor which has enabled this collection to be partially subsidized. We thank the curators of public drug databases, our chemical vendors, and assay teams. We gratefully acknowledge funding sources including NIH LINCS Program grant 3U54 HG006093, NIH BD2K Program grant 5U01HG008699, NIH training grant T32 CA009172, NIH/Harvard Catalyst training award KL2 TR001100, and Conquer Cancer Foundation of ASCO Young Investigator Award.
Please cite usage as: Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, Johnston SE, Vrcic A, Wong B, Khan M, Asiedu J, Narayan R, Mader CC, Subramanian A, Golub TR. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 23, 405–408 (2017).
the Repurposing Hub collection by clinical phase, disease area, mechanism of action, target class, purity and vendor by accessing our web app.
Programmatic access to data is also available through CLUE compute platform API at https://clue.io/api.
any of the three different screening sets:
OPTION 1
320 compounds per 384-well assay-ready plate, with one concentration per compound. Remaining 64 wells contain DMSO or control. Compounds are printed in increments of 2.5 nL using accurate acoustic transfer from a 10mM stock.
OPTION 2
80 compounds per assay-ready plate, with 4-point dilution format for each compound.
us for MTA and access to screening sets. All orders will be processed and managed by the Broad compound management group. Screening can be done in your lab or in collaboration with the Center for the Development of Therapeutics(CDoT) at Broad Institute.
compounds of interest to see their chemical structures and curated annotations.
Download an annotated list with compound metadata.
The Broad Institute offers the repurposing library for optional "cherry-picking" or selection of a limited set of compounds for follow-up hit validation.
your results. Analyze and submit your data back to the Hub to improve compound annotations.
The Hub collection is a shared resource and screening results must be submitted for deposition into the repurposing hub. Collaborators agree to sharing data with other Broad and Broad affiliate members.
Email: repurposing@broadinstitute.org